Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels

被引:0
|
作者
C. Erem
I. Nuhoglu
M. Yilmaz
M. Kocak
A. Demirel
O. Ucuncu
H. Onder Ersoz
机构
[1] Karadeniz Technical University Faculty of Medicine,Department of Internal Medicine, Division of Endocrinology and Metabolism
[2] Division of Hematology,İç Hastalıkları Anabilim Dalı
[3] K.T.Ü. T?p Fakültesi,undefined
来源
Journal of Endocrinological Investigation | 2009年 / 32卷
关键词
Cushing’s syndrome; Hemostasis; thrombin-activatable fibrinolysis inhibitor; tissue factor pathway inhibitor;
D O I
暂无
中图分类号
学科分类号
摘要
Background and objectives: Cushing’s syndrome (CS) is associated with an increased cardiovascular mortality and morbidity. Chronic endogenous and exogenous hypercortisolism frequently induce a hypercoagulable and thrombotic condition. Little is known about hemostatic features of patients with CS. To our knowledge, plasma tissue factor pathway inhibitor (TFPI) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels in these patients have not been investigated. Therefore, the main purpose of this study was to evaluate the markers of endogenous coagulation/fibrinolysis, including TFPI and TAFI, and to investigate the relationships between cortisol and these hemostatic parameters and serum lipid profile in patients with CS. Design and methods: Twenty-four patients with CS and 24 age-matched healthy controls were included in the study. Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factors V, VII, VIII, IX, and X activities, von Willebrand factor (vWF), antithrombin III (AT III), protein C, protein S, tissue plasminogen activator (t-PA), tissue plasminogen activator inhibitor-1 (PAI-1), TFPI and TAFI, as well as common lipid variables, were measured. The relationships between serum cortisol and these hemostatic parameters were examined. Results: Compared with the control subjects, platelet count, PT, fibrinogen, AT-III and PAI-1 were significantly increased in patients with CS (p<0.05, p<0.0001, p<0.01, p<0.05, and p<0.0001, respectively), whereas aPTT and TFPI levels were significantly decreased (p<0.0001 and p<0.01, respectively). Plasma TAFI Ag levels did not significantly change in patients with CS compared with the controls. In patients with CS, we showed a negative correlation between serum cortisol: 08:00 h and aPTT (r:−0.469, p<0.05). Serum cortisol: 24:00 h was positively correlated with PAI-1 Ag levels (r: 0.479, p<0.05). Interpretation and conclusions: In conclusion, we found some important differences in the hemostatic parameters between the patients with CS and healthy controls. Increased platelet count, fibrinogen, PAI-1, and decreased TFPI levels in these patients represent a potential hypercoagulable and hypofibrinolytic state, which might augment the risk for atherosclerotic and atherothrombotic complications. This condition may contribute to the excess of mortality due to cardiovascular disease seen in patients with CS.
引用
收藏
页码:169 / 174
页数:5
相关论文
共 50 条
  • [1] Blood coagulation and fibrinolysis in patients with Cushing's syndrome: Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels
    Erem, C.
    Nuhoglu, I.
    Yilmaz, M.
    Kocak, M.
    Demirel, A.
    Ucuncu, O.
    Ersoz, H. Onder
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (02): : 169 - 174
  • [2] Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism
    Erem, Cihangir
    Kocak, Mustafa
    Nuhoglu, Irfan
    Yilmaz, Mustafa
    Ucuncu, Ozge
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 160 (05) : 863 - 868
  • [3] Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism
    Erem, Cihangir
    Ucuncu, Ozge
    Yilmaz, Mustafa
    Kocak, Mustafa
    Nuhoglu, Irfan
    Ersoz, Halil Onder
    ENDOCRINE, 2009, 35 (01) : 75 - 80
  • [4] Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism
    Erem, Cihangir
    Ucuncu, Ozge
    Yilmaz, Mustafa
    Kocak, Mustafa
    Nuhoglu, Irfan
    Ersoz, Halil Onder
    ENDOCRINE, 2009, 36 (03) : 473 - 478
  • [5] Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism
    Cihangir Erem
    Ozge Ucuncu
    Mustafa Yilmaz
    Mustafa Kocak
    İrfan Nuhoglu
    Halil Onder Ersoz
    Endocrine, 2009, 35 : 75 - 80
  • [6] Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism
    Cihangir Erem
    Ozge Ucuncu
    Mustafa Yilmaz
    Mustafa Kocak
    İrfan Nuhoglu
    Halil Onder Ersoz
    Endocrine, 2009, 36 : 473 - 478
  • [7] Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor
    Aso, Yoshimasa
    FUTURE LIPIDOLOGY, 2006, 1 (04): : 429 - 440
  • [8] Increased Thrombin-Activatable Fibrinolysis Inhibitor and Decreased Tissue Factor Pathway Inhibitor and Thrombomodulin Levels in Children with Hypothyroidism
    Alioglu, Bulent
    Kilic, Nevin
    Simsek, Enver
    Dallar, Yildiz
    JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2012, 4 (03) : 146 - 150
  • [9] Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease
    Koutroubakis, Ioannis E.
    Sfiridaki, Aekaterini
    Tsiolakidou, Georgia
    Coucoutsi, Constantina
    Theodoropoulou, Angeliki
    Kouroumalis, Elias A.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (09) : 912 - 916
  • [10] Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice
    Denorme, Frederik
    Wyseure, Tine
    Peeters, Miet
    Vandeputte, Nele
    Gils, Ann
    Deckmyn, Hans
    Vanhoorelbeke, Karen
    Declerck, Paul J.
    De Meyer, Simon F.
    STROKE, 2016, 47 (09) : 2419 - 2422